| MLTX |
MoonLake Immunotherapeutics |
Class A ordinary share, par value $0.0001 per share |
27.7% |
$142M |
|
19.8M |
|
BVF PARTNERS L P/IL |
Nov 6, 2025 |
| RPTX |
Repare Therapeutics Inc. |
Common Shares, no par value |
24% |
$18.5M |
|
10.3M |
|
BVF PARTNERS L P/IL |
Nov 20, 2025 |
| XOMA |
XOMA Royalty Corp |
Common Stock, $0.0075 par value |
21.6% |
$63.7M |
-$9.66M |
2.59M |
-13.2% |
BVF GP HOLDINGS LLC |
May 16, 2025 |
| GHRS |
GH Research PLC |
Ordinary Shares, nominal value $0.025 per share |
14.2% |
$79.4M |
|
8.83M |
|
BVF PARTNERS L P/IL |
Mar 31, 2025 |
| KURA |
Kura Oncology, Inc. |
Common Stock, par value $0.0001 per share |
9.99% |
$76.8M |
$24.5M |
8.68M |
+46.8% |
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| PVLA |
PALVELLA THERAPEUTICS, INC. |
Common Stock, $0.001 par value per share |
9.99% |
$74M |
|
1.18M |
|
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| CBIO |
CRESCENT BIOPHARMA, INC. |
Ordinary Shares, $0.001 par value per share |
9.99% |
$18.9M |
|
1.39M |
|
BVF PARTNERS L P/IL |
Jun 30, 2025 |
| AVTX |
Avalo Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
9.99% |
$18.5M |
$5.33M |
1.46M |
+40.4% |
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| FDMT |
4D Molecular Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.99% |
$12.3M |
-$534K |
4.63M |
-4.17% |
BVF PARTNERS L P/IL |
Mar 31, 2025 |
| SABS |
SAB Biotherapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.99% |
$10.4M |
|
5.17M |
|
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| IMUX |
IMMUNIC, INC. |
Common Stock, $0.0001 par value |
9.99% |
$8.32M |
|
9.79M |
|
BVF PARTNERS L P/IL |
Jun 30, 2025 |
| TCRX |
TScan Therapeutics, Inc. |
Voting Common Stock, $0.0001 par value per share |
9.99% |
$6.68M |
|
5.26M |
|
BVF PARTNERS L P/IL |
Mar 31, 2025 |
| UNCY |
Unicycive Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
9.99% |
$6.02M |
|
1.42M |
|
BVF PARTNERS L P/IL |
Jun 30, 2025 |
| VTGN |
Vistagen Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
9.97% |
$6.35M |
|
3.08M |
|
BVF PARTNERS L P/IL |
Dec 31, 2024 |
| SEPN |
Septerna, Inc. |
Common Stock, $0.001 par value per share |
9.9% |
$25.1M |
|
4.4M |
|
BVF PARTNERS L P/IL |
Mar 31, 2025 |
| XFOR |
X4 Pharmaceuticals, Inc |
Common Stock, par value $0.001 per share |
9.9% |
$8.8M |
|
2.24M |
|
BVF PARTNERS L P/IL |
Aug 13, 2025 |
| GLUE |
Monte Rosa Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.2% |
$23.9M |
$5.35M |
5.66M |
+28.8% |
BVF PARTNERS L P/IL |
Mar 31, 2025 |
| IKNA |
Ikena Oncology, Inc. |
Common Stock, par value $0.001 per share |
8.3% |
$4.25M |
|
4.01M |
|
BVF PARTNERS L P/IL |
Dec 31, 2024 |
| TYRA |
Tyra Biosciences, Inc. |
Common Stock, $0.0001 par value per share |
7.8% |
$31.4M |
|
3.94M |
|
BVF PARTNERS L P/IL |
Dec 31, 2024 |
| IVVD |
Invivyd, Inc. |
Common Stock, $0.0001 par value per share |
7.4% |
$17.6M |
|
16M |
|
BVF PARTNERS L P/IL |
Oct 15, 2025 |
|
NEKTAR THERAPEUTICS |
Common Stock, $0.0001 par value |
7.4% |
|
|
1.28M |
|
BVF PARTNERS L P/IL |
Jul 1, 2025 |
| IMA |
ImageneBio, Inc. |
Common Stock, par value $0.001 per share |
7.2% |
$6.42M |
|
802K |
|
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| ELEV |
Elevation Oncology, Inc. |
Common Stock, par value $0.0001 per share |
7% |
$1.24M |
|
4.44M |
|
BVF PARTNERS L P/IL |
Mar 31, 2025 |
| XNCR |
Xencor Inc |
Common Stock, par value $0.01 per share |
6.5% |
$54.2M |
|
4.62M |
|
BVF PARTNERS L P/IL |
Oct 9, 2025 |
| GPCR |
Structure Therapeutics Inc. |
Ordinary Shares, par value $0.0001 per share |
5.6% |
$181M |
|
9.61M |
|
BVF PARTNERS L P/IL |
Aug 11, 2025 |
| ZYME |
Zymeworks Inc. |
Common Stock, $0.00001 par value per share |
5.2% |
$67.3M |
|
3.94M |
|
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| CMPX |
Compass Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
5.1% |
$30.6M |
|
8.75M |
|
BVF PARTNERS L P/IL |
Oct 22, 2025 |
| IVA |
Inventiva S.A. |
Ordinary Shares, nominal value (euro)0.01 per share |
4.99% |
$39.7M |
$4.25M |
9.57M |
+12% |
BVF PARTNERS L P/IL |
Nov 17, 2025 |
| CDTX |
Cidara Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
4.4% |
$114M |
-$21.5M |
1.19M |
-15.9% |
BVF PARTNERS L P/IL |
Oct 15, 2025 |
| PTGX |
Protagonist Therapeutics, Inc |
Common Stock, $0.00001 par value per share |
4.1% |
$170M |
-$43.2M |
2.56M |
-20.2% |
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| VSTM |
Verastem, Inc. |
Common Stock, $0.0001 par value per share |
3.9% |
$22.7M |
-$29.2M |
2.5M |
-56.3% |
BVF PARTNERS L P/IL |
Aug 11, 2025 |
| ETNB |
89bio, Inc. |
Common Stock, par value $0.001 per share |
3.6% |
$31.5M |
|
4.33M |
|
BVF PARTNERS L P/IL |
Dec 31, 2024 |
| CTMX |
CytomX Therapeutics, Inc. |
Common Stock, $0.00001 par value per share |
3.5% |
$14.4M |
-$14.4M |
5.77M |
-50% |
BVF PARTNERS L P/IL |
Jul 3, 2025 |
| MIRM |
Mirum Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
3% |
$110M |
|
1.5M |
|
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| ENGN |
enGene Holdings Inc. |
Common Shares, no par value per share |
1.8% |
$3.78M |
-$8.42M |
945K |
-69% |
BVF PARTNERS L P/IL |
Jan 27, 2025 |
| CELC |
Celcuity Inc. |
Common Stock, $0.001 par value per share |
1.6% |
$32.5M |
|
658K |
|
BVF PARTNERS L P/IL |
Sep 30, 2025 |
|
NewcelX Ltd. |
Common Shares, par value CHF 0.05 |
0.6% |
|
|
28.7K |
|
BVF PARTNERS L P/IL |
Oct 31, 2025 |
| FBRX |
Forte Biosciences, Inc. |
Common Stock, $0.001 par value |
0.5% |
$980K |
-$8.67M |
65.4K |
-89.8% |
BVF PARTNERS L P/IL |
Sep 30, 2025 |
| OVID |
Ovid Therapeutics Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
Jul 17, 2025 |
| ALLK |
Allakos Inc. |
Common Stock, par value $0.001 |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
May 15, 2025 |
| VIGL |
Vigil Neuroscience, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
-$38.1M |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
Jun 30, 2025 |
| THRD |
Third Harmonic Bio, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
Apr 14, 2025 |
| VERV |
Verve Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
Jun 30, 2025 |
| ITOS |
iTeos Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
0% |
$0 |
-$31.4M |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
Jun 30, 2025 |
| EPIX |
ESSA Pharma Inc. |
Common Shares |
0% |
$0 |
-$2.8M |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
Oct 9, 2025 |
| RAPT |
RAPT Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
-$303M |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
Sep 30, 2025 |